Valneva has been granted a patent for an immunogenic polypeptide derived from the C-terminal domain of Borrelia’s outer surface protein A (OspA). This polypeptide, which includes specific epitopes from various Borrelia strains, aims to induce protective immune responses against Lyme Borreliosis. GlobalData’s report on Valneva gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Valneva, Anti-viral antigen-based compositions was a key innovation area identified from patents. Valneva's grant share as of June 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Vaccine for treating or preventing borrelia infections
The granted patent US12018054B2 describes an immunogenic polypeptide derived from the C-terminal domain of the outer surface protein A (OspA) of Borrelia, which is implicated in Lyme Borreliosis. This polypeptide is characterized by the inclusion of at least three specific OspA epitopes from distinct Borrelia strains, enabling it to induce a protective immune response against these strains. The patent specifies that the C-terminal OspA domain can be selected from several defined sequences (SEQ ID NO: 9, 10, 12, 13) and their immunogenic variants, which must maintain at least 95% sequence identity. Additionally, the three-dimensional structure of the polypeptide is stabilized through the introduction of at least two cysteine residues that form disulfide bonds, enhancing its immunogenic properties.
The patent further outlines various formulations and applications of the immunogenic polypeptide, including its use in pharmaceutical compositions, particularly vaccines. These compositions may contain additional antigens from other Borrelia species or tick-borne pathogens, as well as immunostimulatory substances to enhance the immune response. The claims also cover methods for treating or preventing Borrelia infections, specifying a range of Borrelia species that the immunogenic polypeptide targets. The versatility of the polypeptide, including its potential as a fusion protein and its incorporation of lipidation signals, positions it as a promising candidate for vaccine development against Lyme disease and related infections.
To know more about GlobalData’s detailed insights on Valneva, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
